Table 2.
Molecular alterations in the three parts of the stomach in patients with non-IM and IM among the Hp, AG, and GC groups.
| No. of patients with non-IM | Hp group (n = 21) | AG group (n = 30) | GC group (n = 27) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antrum | Angulus | Corpus | P | Antrum | Angulus | Corpus | P | Antrum | Angulus | Corpus | P | ||||||||||
| 14* | (%) | 9 | (%) | 18 | (%) | 25 | (%) | 14 | (%) | 28 | (%) | 13 | (%) | 9* | (%) | 23 | (%) | ||||
| MSI | 0 | (0) | 1 | (11.1) | 0 | (0) | 0.16 | 0 | (0) | 0 | (0) | 1 | (3.6) | 0.49 | 2 | (15.4) | 0 | (0) | 2 | (8.7) | 0.46 |
| CIMP | 7 | (50.0) | 6 | (66.7) | 13 | (72.2) | 0.42 | 0 | (0) | 0 | (0) | 0 | (0) | — | 1 | (7.7) | 2 | (22.2) | 0 | (0) | 0.08 |
| CDH1 | 12 | (85.7) | 7 | (77.8) | 18 | (100) | 0.15 | 9 | (36.0) | 6 | (42.9) | 8 | (28.6) | 0.64 | 4 | (30.8) | 6 | (66.7) | 11 | (47.8) | 0.25 |
| CDKN2A | 1 | (7.1) | 1 | (11.1) | 3 | (16.7) | 0.71 | 0 | (0) | 0 | (0) | 0 | (0) | — | 1 | (7.7) | 1 | (11.1) | 0 | (0) | 0.31 |
| MLH1 | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — |
| MGMT | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — |
| MINT1 | 10 | (71.4) | 8 | (88.9) | 14 | (77.8) | 0.61 | 1 | (4.0) | 1 | (7.1) | 1 | (3.6) | 0.86 | 1 | (7.7) | 2 | (22.2) | 0 | (0) | 0.08 |
| MINT31 | 8 | (57.1) | 6 | (66.7) | 14 | (77.8) | 0.46 | 2 | (8.0) | 0 | (0) | 0 | (0) | 0.18 | 3 | (23.1) | 2 | (22.2) | 0 | (0) | 0.05 |
| RUNX3 | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 1 | (11.1) | 0 | (0) | 0.13 |
| miR-124a-3 | 3 | (21.4) | 4 | (44.4) | 6 | (33.3) | 0.50 | 1 | (4.0) | 0 | (0) | 0 | (0) | 0.43 | 3 | (23.1) | 0 | (0) | 0 | (0) | 0.02 |
| miR-34c | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 2 | (8.7) | 0.37 |
| No. of patients with IM | 6 | (%) | 12 | (%) | 3 | (%) | P | 5 | (%) | 16 | (%) | 2 | (%) | P | 14 | (%) | 17 | (%) | 4 | (%) | P |
| MSI | 3 | (50.0) | 5 | (41.7) | 0 | (0) | 0.32 | 1 | (20.0) | 3 | (18.8) | 0 | (0) | 0.79 | 3 | (21.4) | 2 | (11.8) | 0 | (0) | 0.51 |
| CIMP | 1 | (16.7) | 5 | (41.7) | 1 | (33.3) | 0.57 | 1 | (20.0) | 2 | (12.5) | 0 | (0) | 0.77 | 8 | (57.1) | 11 | (64.7) | 0 | (0) | 0.06 |
| CDH1 | 1 | (16.7) | 5 | (41.7) | 1 | (33.3) | 0.57 | 0 | (0) | 2 | (12.5) | 0 | (0) | 0.62 | 3 | (21.4) | 4 | (23.5) | 0 | (0) | 0.56 |
| CDKN2A | 0 | (0) | 0 | (0) | 0 | (0) | — | 1 | (20.0) | 0 | (0) | 0 | (0) | 0.15 | 0 | (0) | 0 | (0) | 0 | (0) | — |
| MLH1 | 0 | (0) | 0 | (0) | 0 | (0) | — | 0 | (0) | 0 | (0) | 0 | (0) | - | 0 | (0) | 0 | (0) | 0 | (0) | — |
| MGMT | 1 | (16.7) | 0 | (0) | 0 | (0) | 0.27 | 0 | (0) | 0 | (0) | 0 | (0) | — | 1 | (7.1) | 2 | (11.8) | 0 | (0) | 0.73 |
| MINT1 | 3 | (50.0) | 9 | (75.0) | 1 | (33.3) | 0.32 | 3 | (60.0) | 13 | (81.3) | 2 | (100) | 0.45 | 11 | (78.6) | 14 | (82.4) | 1 | (25.0) | 0.06 |
| MINT31 | 1 | (16.7) | 10 | (83.3) | 1 | (33.3) | 0.02 | 5 | (100) | 5 | (31.3) | 0 | (0) | 0.01 | 12 | (85.7) | 11 | (64.7) | 1 | (25.0) | 0.06 |
| RUNX3 | 1 | (16.7) | 4 | (33.3) | 1 | (33.3) | 0.75 | 2 | (40.0) | 3 | (18.8) | 0 | (0) | 0.45 | 9 | (64.3) | 8 | (47.1) | 0 | (0) | 0.07 |
| miR-124a-3 | 6 | (100) | 12 | (100) | 3 | (100) | — | 5 | (100) | 13 | (81.3) | 1 | (50.0) | 0.28 | 12 | (85.7) | 15 | (88.2) | 4 | (100) | 0.73 |
| miR-34c | 5 | (83.3) | 8 | (66.7) | 0 | (0) | 0.046 | 3 | (60.0) | 8 | (50.0) | 1 | (50.0) | 0.92 | 7 | (50.0) | 10 | (58.8) | 3 | (75.0) | 0.66 |
IM, intestinal metaplasia; MSI, microsatellite instability; CIMP, CpG island methylator phenotype.
*One sample in the Hp group and one sample in the GC group could not be analyzed due to a small sample.